•
Mar 31, 2022
Mink Therapeutics Q1 2022 Earnings Report
Reported financial results for the first quarter 2022 and provided a corporate business update.
Key Takeaways
MiNK Therapeutics reported a net loss of $7.8 million for Q1 2022, which includes non-cash expenses of $813,000. The company's cash balance at the end of the quarter was $34.7 million.
Advanced ongoing clinical programs, manufacturing platform, and differentiated pipeline.
On track for data readouts this year designed to underscore the characteristics of iNKT cells.
Potential to expand durability of clinical benefit with favorable tolerability.
MiNK Internal Manufacturing Capabilities Ready for GMP Launch.